论文部分内容阅读
目的:分析左西孟旦联合脑心通胶囊治疗急性心力衰竭的临床疗效及对血清氨基末端B型钠尿肽前体(NT-proBNP)、半乳糖凝集素(Galectin-3)、内皮素-1(ET-1)、半胱氨酸蛋白酶抑制剂C(CystatinC)水平的影响。方法:选取2015年3月至2016年6月我院收治的90例急性心力衰竭患者,按抽签法将患者随机分为观察组(n=45)和对照组(n=45),对照组患者给予单纯左西孟旦治疗,观察者患者在此基础上联合应用脑心通胶囊治疗。比较两组患者的临床疗效、心功能指标、血压、心率、不良反应的发生情况及治疗前后血清NT-proBNP、Galectin-3、ET-1和CystatinC水平的变化。结果:治疗后,观察组总有效率为93.33%,比对照组显著升高(77.78%)(P<0.05)。两组治疗后患者的左室部分缩短(LVFS)、左心射血分数(LVEF)、每搏输出量(SV)水平均较治疗前增高,血压、心率及血清NT-proBNP、Galectin-3、ET-1、CystatinC水平均较治疗前明显下降,且观察组患者的LVFS、LVEF、SV水平明显高于对照组(P<0.05),血压、心率及血清NT-proBNP、Galectin-3、ET-1、CystatinC水平明显低于对照组(P<0.05)。结论:左西孟旦联合脑心通胶囊治疗能提高急性心力衰竭的治疗效果,显著降低血清NT-proBNP、Galectin-3、ET-1和CystatinC水平,安全性较高。
OBJECTIVE: To analyze the clinical efficacy of levosimendan combined with Naoxintong capsule in the treatment of acute heart failure, and to evaluate the clinical efficacy of levosimendan combined with Naoxintong capsule in the treatment of acute heart failure. 1 (ET-1) and cystatin C (Cst). Methods: Ninety patients with acute heart failure admitted to our hospital from March 2015 to June 2016 were randomly divided into observation group (n = 45) and control group (n = 45) according to the method of lottery. Patients in the control group Given a simple levosimendan treatment, the observer patients on the basis of this combination Naoxintong capsule treatment. The clinical efficacy, cardiac function, blood pressure, heart rate, adverse reactions and changes of serum NT-proBNP, Galectin-3, ET-1 and CystatinC before and after treatment were compared between the two groups. Results: After treatment, the total effective rate in observation group was 93.33%, which was significantly higher than that in control group (77.78%) (P <0.05). LVFS, LVEF and SV of the two groups were higher than before treatment, blood pressure, heart rate, serum NT-proBNP, Galectin-3, ET-1, CystatinC levels were significantly lower than those before treatment, and LVFS, LVEF and SV levels in the observation group were significantly higher than those in the control group (P <0.05). Blood pressure, heart rate and serum NT-proBNP, Galectin-3, ET- 1, CystatinC level was significantly lower than the control group (P <0.05). Conclusion: Levosimendan combined with Naoxintong capsule can improve the therapeutic effect of acute heart failure and significantly reduce the serum levels of NT-proBNP, Galectin-3, ET-1 and CystatinC, with higher safety.